OptiBiotix Health PLC Directorate Change (5081K)
05 January 2021 - 6:00PM
UK Regulatory
TIDMOPTI
RNS Number : 5081K
OptiBiotix Health PLC
05 January 2021
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Director Appointment
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high choleste
r ol, diabetes and skincare, a nn o unces that further to the
announcement made on 9 December 2020 regarding the intention to
appoint Christopher Brinsmead CBE as a Director of the Company, the
regulatory due diligence process required for a Board position has
been completed, and Chris joined the Board as a Non-Executive
Director on 1 January 2021. The text below sets out the required
disclosures.
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for
Companies, the following information is disclosed in respect of
Christopher David Brinsmead (aged 61):
Current Appointments Appointments in the last five years
CDB (Meadowside) Limited Bamburgh Capital Limited
----------------------------------------------
Peakdata AG Cambian Group plc (now Cambian Group Limited)
----------------------------------------------
Proveca Limited Collagen Solutions plc
----------------------------------------------
Scapa Group plc Consort Medical plc (now Consort Medical
Limited)
----------------------------------------------
Datapharm Communications Limited
----------------------------------------------
Kinapse Limited
----------------------------------------------
UDG Healthcare plc
----------------------------------------------
Wesleyan Administration Services Limited
----------------------------------------------
Welseyan Assurance Society
----------------------------------------------
Christopher Brinsmead CBE does not currently own any shares or
options in the Company.
There is no further information regarding Christopher Brinsmead
CBE required to be disclosed under the AIM Rules.
Neil Davidson, Chairman of OptiBiotix commented: "We are pleased
to confirm the appointment of Chris to the OptiBiotix Board.
Chris's appointment comes at a critical point in the Company's
development as it continues to grow sales and expand into
international markets with its first generation products, and
commercialise its next generation microbiome modulating,
SweetBiotix, and drug biotherapeutic products. Chris's
pharmaceutical, healthcare, investment, and board experience with a
FTSE 350 company complements the current Boards wealth of
experience."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
The Directors of the Company accept responsibility for the
content of this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook
Stephen O'Hara, Chief Executive below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI) is a biotechnology company
formed in March 2012 which, brings science and human stuidies to
the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to
prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than seventy international food and
healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a
wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding OptiBiotix's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAQZLFBFFLEBBQ
(END) Dow Jones Newswires
January 05, 2021 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024
